6 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 6, Active not recruiting 3, Recruiting 2, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis Ozanimod, Fingolimod, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Recruiting | Bristol-Myers Squibb | 194 | 2025-04-08 | 2026-09-10 |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab, Ocrelizumab Placebo, Fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 188 | 2022-05-19 | 2026-07-15 |
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Fingolimod, Ofatumumab, Siponimod - Multiple Sclerosis (MS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 129 | 2021-10-05 | 2026-05-14 |
| Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients Fingolimod, Fish Oil, Placebo (for Fish Oil) - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 50 | 2015-04-01 | 2019-05-14 |
| Safety and Efficacy of Fingolimod in MS Patients in China fingolimod, Placebo (6mos) + open label fingolimod (6 mos) - Multiple Sclerosis (Relapsing Remitting) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-06-01 | 2017-04-21 | |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Interferon beta-1a, Fingolimod, Placebo capsule - Multiple Sclerosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 240 | 2013-07-26 | 2026-08-10 |
| Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Fingolimod, Placebo Comparator - Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | Completed | Novartis Pharmaceuticals | 106 | 2012-12-22 | 2017-10-30 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 1064 | 2012-08-09 | 2019-05-28 |
| Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis Fingolimod - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 162 | 2012-02-01 | 2015-03-19 |
| Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod Fingolimod, Placebo - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 142 | 2011-09-01 | 2014-08-08 |
| Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 4125 | 2010-09-13 | 2021-04-21 |
| Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) Fingolimod, Placebo, Seasonal influenza vaccine - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis | 138 | 2010-08-01 | 2012-06-19 |
| Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Fingolimod, Placebo - Multiple Sclerosis | Phase 3 | Completed | Novartis | 1083 | 2006-06-01 | 2012-08-07 |
Multiple Sclerosis (9) · Multiple Sclerosis, Relapsing-Remitting (6) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Recurrence (1) · Thinness (1)
Novartis Pharmaceuticals (8) · Novartis (2) · Biogen (1) · Bristol-Myers Squibb (1) · Hoffmann-La Roche (1) · Isfahan University of Medical Sciences (1) · TG Therapeutics, Inc. (1)
Poland (9) · United States (9) · Australia (8) · Canada (8) · Spain (8) · Italy (7) · Austria (6) · Brazil (6) · France (6) · Germany (6) · Mexico (6) · United Kingdom (6) · Argentina (5) · Belgium (5) · Romania (5)
Shaygannejad Shaygannejad, M.D. (1)
PMID 24051419, PMID 24685276, PMID 25245812, PMID 26121423, PMID 26170105, PMID 27733070, PMID 28856176, PMID 30001923, PMID 30207920, PMID 31467033, PMID 31598139, PMID 32852530, PMID 36286605, PMID 39812825
2023 (2), 2025 (1)